Steady growth and dynamic presence in domestic and international markets
VIANEX SA, the leading Greek pharmaceutical company founded by Paul Giannacopoulos, has been active in the pharmaceutical industry since 1924. With a tradition of more than 95 years, the company boasts a wide business scope, including production, marketing, export and distribution of pharmaceuticals in all therapeutic categories. With a leading presence in the Greek, but also the European markets, the vision of VIANEX and Mr. Dimitris P. Giannakopoulos, President of BoD & CEO of the Group, is to continue to evolve and expand its presence and know-how worldwide.
VIANEX has proven its dynamic presence in the industry, presenting sustainable development and continuous improvement in both its products and sizes. In particular, during the past decade, VIANEX posted a steady upward trend in all the areas of its activities. In its most recent results (2019), the firm posted consolidated sales of 301.3 million euros, recording a significant increase of 8.8% compared to 2018, and a double-digit increase of 19.4 % against the two years 2017-2018.
VIANEX’s modern business production model also includes broad investment programs combined with internationally oriented strategic business moves. Exports, being of particular importance to the company, accounted for 20% of total sales in 2019. The firm’s constantly increasing export activity has led to its presence with approved products in 56 countries worldwide. Its strong export dynamic has been growing rapidly over the past decade: the company’s exports skyrocketed from 18.7 million euros in 2010 to 51.2 million euros in 2019, recording an impressive increase of 173%.
The firm regards human resources as its largest asset. VIANEX actively supports employment in Greece, while contributing to the recovery of the national economy. Total recruitment in the past decade amounted to 727 jobs, while the average recruitment per year amounts to 66 employees. Current staff amounts to 1,258, having grown as mush as 21% over the past decade. The company implements best practices at the level of corporate governance based on meritocracy and transparency, with 57% of staff being male and 43% female.
The company retains a constantly expanding product portfolio with the addition of new partnerships and formulations, providing even more impetus to VIANEX. Major international pharmaceutical companies have proven their timeless trust both in VIANEX and VIAN, a Giannakopoulos Group subsidiary, for the production, representation and marketing of their products.
Some of the deals renewed in recent years are with the international pharmaceutical companies JANSSEN and MSD. A milestone in 2019 was VIANEX’s acquisition of the company PHARMANEL SA, a move aimed at further strengthening its business in the generic market.
For the VIANEX Group, responsibility towards man and society is a commitment and a duty. The company always stands by our fellow human beings and those in need of support, implementing several projects, actions and charitable activities of a wide positive footprint.